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procedure, physician visits, and contraceptive method failures.
Effectiveness was deﬁned as both control of uterine bleed and
contraception success. We studied three clinical scenarios: sce-
nario 1 compared LNG-IUS with OC in women who responded
to initial trials of OCs; scenario 2 compared surgery with LNG-
IUS among women who did not respond to an initial trial of
OCs; and scenario 3 compared LNG-IUS and OC for women
who are naïve to medical therapy. In all scenarios, surgery fol-
lowed if medical therapy failed. RESULTS: In scenario 1, LNG-
IUS was both more effective (92% vs. 90.4%) and less expensive
($2796 vs. $4711) than OC. In scenario 2, surgical management
was slightly more effective than LNG-IUS (95.5% vs. 92.0%
success rate) but at a much higher cost ($4m853 vs. $2,796 per
woman), and was associated with an additional cost of approx-
imately $60,000 per additional successfully treated woman. In
scenario 3, LNG-IUS achieved similar outcomes compared to
OCs (92% vs. 93.6%) but at a much lower cost ($2796 vs.
$4895). The results of the model were robust over changes of
assumptions and variations of key variables. CONCLUSIONS:
The treatment strategy with LNG-IUS was the most cost-
effective approach to managing AUB, regardless of whether or
not a woman had tried or failed OC therapy.
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ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA
AND METASTATIC LIVER DISEASE PATIENTS: A PRIVATE
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OBJECTIVES: Published data on costs associated with treating
privately insured patients with hepatocellular carcinoma (HCC)
or metastatic liver disease (MLD) are limited. This study evalu-
ated health resource use and medical care costs in newly diag-
nosed HCC and MLD patients. METHODS: Patients diagnosed
with HCC or MLD in 2002 were identiﬁed from a nationally
representative private payer claims database by ICD-9 diagnosis
codes, using the date of the ﬁrst diagnosis as the “index date”.
Patients were required to be 18 years of age or older, with no
prior HCC or MLD diagnosis, and continuously enrolled in a
health plan. Health resource use and medical care costs were
tracked over one year. RESULTS: The study included 297 HCC
and 846 MLD patients. The mean age for all patients was 56.8
years and 41% were male. MLD patients had signiﬁcantly higher
inpatient admissions versus HCC patients (2.1 vs. 1.5, p <
0.001), while the mean aggregate hospital days was signiﬁcantly
longer in HCC patients (16.5 vs. 14.2, p < 0.001). MLD patients
also had signiﬁcantly greater emergency room, outpatient hos-
pital, and physician ofﬁce visits (p < 0.05). Total mean medical
costs were signiﬁcantly higher in MLD patients ($93,786) versus
HCC patients ($37,203, p < 0.001). These higher costs were due
primarily to signiﬁcantly greater ancillary costs in MLD patients
($54,671 vs. $5,903, p < 0.001), which include costs associated
with chemotherapy. All differences remained signiﬁcant after
adjusting for differences in age and sex. CONCLUSIONS:
Among managed care patients newly diagnosed with HCC or
MLD, signiﬁcantly higher 1-year health resource use and medical
care costs were found for MLD patients. The difference in overall
costs was due primarily to the higher use of ancillary services
among MLD patients. These ﬁndings provide important new
data for evaluating the economic impact of treating HCC and
MLD patients.
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OBJECTIVES: Estimate national trends in mammography
screening use among elderly Medicare beneﬁciaries for the period
of 1998 to 2001; determine the extent to which socio-
demographic, clinical, and access factors are associated with 
disparities in screening use. METHODS: A secondary data
analysis of the Medicare Current Beneﬁciary Survey (MCBS) was
conducted. Community-dwelling women aged >65 years who
completed the MCBS at least once during the survey years of
1998 to 2001 were included. Having had a mammogram in the
past year was determined by a participant’s response to the ques-
tion “have you had a mammogram or a breast x-ray since a year
ago?”, or by a Medicare claim coded with a mammogram pro-
cedure in the calendar year. Multivariate logistic regression was
used to estimate the association between the likelihood of having
had mammogram in the past year and factors, such as socio-
demographic, biological, and access factors. Sampling weights
were used to reﬂect national estimates of Medicare beneﬁciaries.
Standard errors were adjusted for clustering and stratiﬁcation in
the complex sampling design. RESULTS: A total of 10,757
females 65 years of age or older responded to the MCBS from
1998 to 2001 (weighted N = 34 million). Over half (54%, 95%
CI 53%–55%) of the respondents had mammogram in the past
year. Annual mammography screening rates increased over time,
from 49% in 1998 to 58% in 2001. In adjusted models, there
was no signiﬁcant racial or ethnic disparity in mammography
use, but the other socio-demographic factors remained signiﬁ-
cantly associated with lower odds of mammography use. CON-
CLUSIONS: Mammography screening rates increased notably
between 1998 and 2001 in the Medicare population. While no
racial or ethnic disparities in screening rates were noted in this
study, lower income, less education, no insurance and being
unmarried were identiﬁed as barriers to breast cancer screening
for elderly Medicare beneﬁciaries.
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OBJECTIVE: In the late 1990’s, a U.S. health policy initiative
recommended that colorectal cancer screening begin at age 50
for all adults. Shortly thereafter, Medicare began paying for
screening colonoscopy in average risk persons. In the years that
followed, the mix of procedures performed to evaluate colon
health in Medicare beneﬁciaries changed; colonoscopy proce-
dures increased and other colorectal cancer screening procedures
decreased. We conducted this study to evaluate trends in col-
orectal cancer screening procedure volumes in private-pay
patients between 2000 and 2004. METHODS: A nationally rep-
resentative private payer claims database was used to identify
patient records with claims for colonoscopy, ﬂexible sigmoi-
doscopy, double-contrast barium enema, and fecal occult blood
test (FOBT) during 2000–2004. CPT and HCPCS procedure
codes were used to identify patient records with claims for the
procedures of interest. Only patients aged 18+ were included in
the analysis. RESULTS: Patients in the study sample averaged 53
years of age and were 60% female. From 2000 to 2004 the pro-
portion of screening procedures performed relative to the
number of plan members increased 38% (8% to 11%). Relative
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to the total number of screening procedures performed, colono-
scopies increased 60% (20% to 32%; p = 0.01), ﬂexible sig-
moidoscopy decreased 75% (8% to 2%; p = 0.01), barium
enema decreased 50% (2% to 1%; p = 0.01), and FOBT
decreased 6% (70% to 66%). Gastroenterologists performed an
increasingly large proportion of the colonoscopy procedures
(68% in 2000 vs. 73% in 2004). CONCLUSIONS: Colorectal
cancer screening in the private sector increased between 2000
and 2004. During this time, there was a substantial increase in
the use of colonoscopy and a marked decrease in the use of ﬂex-
ible sigmoidoscopy and barium enema. Additional research is
needed to track trends in these procedures and evaluate their
impact on health policy goals, patient outcomes, and system
capacity.
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OBJECTIVES: Epoetin alfa (EPO) and darbepoetin alfa (DARB)
are two erythropoietic stimulating therapies (ESTs) indicated for
the treatment of chemotherapy-induced anemia. This analysis
compared recent dosage patterns and associated drug costs of
EPO and DARB in hospitalized cancer patients. METHODS: An
analysis of electronic inpatient hospital records from the Premier
Perspective Comparative Hospital Database was conducted.
Study subjects were identiﬁed through hospitalizations recorded
between July 2002 and March 2005 from over 500 hospitals
nationwide. Included were patients ≥18 years of age with a
primary admitting diagnosis of cancer who were treated with
EPO or DARB during their hospital stay. Patients who had
received renal dialysis were excluded. To minimize effect of out-
liers, 5% of patients with extreme doses in each group were
excluded from the dosing analysis. Wholesale acquisition costs
in 2005 (EPO: $0.01217/Unit, DARB: $4.36/mcg) were used to
calculate EST costs. RESULTS: A total of 27,804 patients were
identiﬁed (EPO: 24,814, DARB: 2990). Mean age and gender
distribution were comparable between groups (age: EPO 65.3
years, DARB 64.5 years; % women: EPO 53%, DARB 55%).
Mean cumulative dose per inpatient stay was EPO 61,656 ±
50,274 Units and DARB 259 ± 340mcg, corresponding to a dose
only ratio of 238 :1 (Units EPO: mcg DARB). Average treatment
cost was signiﬁcantly lower in the EPO group, compared to
DARB (EPO: $750, DARB: $1129; p < 0.0001). CONCLU-
SION: This analysis utilizing inpatient data demonstrated a dose
only ratio between EPO and DARB of 238 :1 in patients with
cancer. DARB was found to cost 51% more than EPO based on
the cumulative dose administered during hospitalization.
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OBJECTIVES: The objective of this study was to determine
incremental direct expenditures of treating hypertension in the
U.S. non-institutionalized population. METHODS: Analysis of
2001 Medical Expenditure Panel Survey (MEPS) data, a national
probability sample survey of 33,556 individuals from the civil-
ian non-institutionalized U.S. population was conducted. Hyper-
tensive patients were identiﬁed as those with hypertension based
ICD-9 codes, i.e., 401-xx-405-xx for medical conditions or
medical events, including inpatient visits, outpatient visits, emer-
gency room visits, home-health visits, ofﬁce-based medical
provider visits, and other medical expenses, or patients who self-
reported being diagnosed with hypertension by their physician,
or patients who were prescribed an anti-hypertensive medication
listed in seventh report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of Hypertension,
unless there was an indication that the medication was pre-
scribed for a medical condition other than hypertension. Only
individuals 18 years of age or older were included. Incremental
expenditures for treating hypertension were estimated through
least squares regression adjusting for age, gender, race, educa-
tion, and co-morbidities using the D’Hoore version of the Charl-
son co-morbidity index. Sample data were projected to the U.S.
population and 95% conﬁdence limits for estimates were calcu-
lated using the Taylor expansion method. RESULTS: Sample
estimates projected to the population indicated that approxi-
mately 17.4% of individuals aged 18 years and above in the
ambulatory population have hypertension. Total incremental
annual direct expenditures for hypertension patients were esti-
mated to be more than $US 54.0 billion in 2001 after adjusting
for demographics and co-morbidities. Mean incremental annual
direct expenditures for an individual with hypertension was $US
1131. Prescription medicines, inpatient visits, and outpatient
visits constituted more than 90% of overall incremental expen-
ditures. CONCLUSIONS: With incremental direct medical
expenditures estimated at nearly $US55.0 billion, hypertension
expenditures represent a signiﬁcant amount of health care
resource utilization.
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Wang F1, Iyer S2, Ciuryla V2, Feng_Wang P3
1Cephalon, Inc, Fraser, PA, USA, 2Wyeth Research, Collegeville, PA,
USA, 3Premier Healthcare Informatics, Charlotte, NC, USA
OBJECTIVES: To determine the impact of ventricular arrhyth-
mia on mortality and health care resource utilization in hospi-
talized patients with acute myocardial infarction (AMI).
METHODS: A retrospective cohort study design was used.
Adult patients with primary diagnosis of AMI (ICD-9 code:
410.x1), between July 2003 and June 2004, were identiﬁed from
a large retrospective database of 800 hospitals in the United
States. The AMI patients were further classiﬁed based on sec-
ondary diagnosis of ventricular arrhythmia into three groups:
AMI with sustained ventricular tachycardia (sustained VT)/ven-
tricular ﬁbrillation (VF) (ICD-9 code: 427.4x, 427.5); AMI with
paroxysmal ventricular tachycardia (PVT) (ICD-9 code 427.1);
and AMI without ventricular arrhythmia. Mortality rates, length
of hospital stay and cost were compared between the groups
using chi-square and ANOVA tests. RESULTS: A total of 91,225
patients with primary diagnosis of AMI were identiﬁed, of which
8125 (8.9%) patients had a secondary diagnosis of ventricular
arrhythmia, including sustained VT/VF (N = 3004; 3.3%) and
PVT (N = 5121; 5.6%). A majority of the AMI patients with
ventricular arrhythmia were male (70.2%), caucasian (73.4%)
and ≥65 years (55%). In-hospital mortality rates were higher in
the AMI patients with sustained VT/VF (28.5%) and PVT
(7.9%), than AMI patients without ventricular arrhythmia
(6.2%). The average hospital length of stay was signiﬁcantly
higher (p < 0.001) in AMI patients with sustained VT/VF (8.0 ±
